CALC

SEC source: 0001823197-26-000002 · form4-10052026_091008.xml · derivative · entry 1

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001674797-26-000007 · form4-10052026_091046.xml · derivative · entry 1

Zaytsev Evgeny · CIK 0001674797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001825009-26-000003 · form4-10052026_091056.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001626850-26-000002 · form4-10052026_091056.xml · derivative · entry 1

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001189022-26-000005 · form4-10052026_091035.xml · derivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001968793-26-000007 · form4-09282026_080927.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2036-09-23

F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.

SEC source: 0001942596-26-000003 · form4-09282026_080935.xml · derivative · entry 1

Bardin Stephen · CIK 0001942596 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2036-09-23

F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.

SEC source: 0001969388-26-000003 · form4-09282026_080937.xml · derivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2036-09-23

F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.

SEC source: 0001484729-26-000006 · form4-09282026_080938.xml · derivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2036-09-23

F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.

SEC source: 0001968793-26-000006 · form4-08212026_100852.xml · derivative · entry 2

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,486

Underlying: Common Stock · 124,486 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001968793-26-000006 · form4-08212026_100852.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,486

Underlying: Common Stock · 124,486 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 3

Zaytsev Evgeny · CIK 0001674797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 2

Zaytsev Evgeny · CIK 0001674797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bering Partners II, L.P.

Disclosed balance after: 1,450,267

Underlying: Common Stock · 1,450,267 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F4 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F4 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F3 · ownership.nature: The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

SEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 1

Zaytsev Evgeny · CIK 0001674797 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bering Partners II, L.P.

Disclosed balance after: 1,450,267

Underlying: Common Stock · 1,450,267 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F3 · ownership.nature: The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.

SEC source: 0001484729-26-000005 · form4-08212026_100832.xml · derivative · entry 2

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,729

Underlying: Common Stock · 186,729 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001484729-26-000005 · form4-08212026_100832.xml · derivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,729

Underlying: Common Stock · 186,729 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 3

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F4 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 2

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,182,621

Underlying: Common Stock · 1,182,621 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001189022-26-000004 · form4-08212026_100838.xml · derivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,182,621

Underlying: Common Stock · 1,182,621 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001626850-26-000001 · form4-08212026_100848.xml · derivative · entry 1

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001823197-26-000001 · form4-08212026_100824.xml · derivative · entry 1

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001825009-26-000002 · form4-08212026_100850.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001576244-26-000005 · form4-08212026_100837.xml · derivative · entry 2

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,729

Underlying: Common Stock · 186,729 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F3 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

SEC source: 0001576244-26-000005 · form4-08212026_100837.xml · derivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,729

Underlying: Common Stock · 186,729 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.

SEC source: 0000912282-26-001157 · form4.xml · derivative · entry 3

ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,529,192

Underlying: Common Stock · 3,529,192 shares

Expires 2031-06-23

F3 · derivative.exercise_date: The issue date of the Series B Warrants is August 19, 2026.

SEC source: 0000912282-26-001157 · form4.xml · derivative · entry 2

ALAFI CAPITAL CO LLC · CIK 0001216017 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,529,192

Underlying: Common Stock · 3,529,192 shares

Expires not disclosed

F1 · derivative.exercise_date: The issue date of the Series A Warrants is August 19, 2026.

F2 · derivative.expiration_date: The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.

SEC source: 0001674797-26-000004 · form4-07072026_090755.xml · derivative · entry 1

Zaytsev Evgeny · CIK 0001674797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-07-01

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant.

SEC source: 0001968793-26-000004 · form4-06292026_080607.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,025

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001484729-26-000004 · form4-06292026_080601.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,655

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001267959-26-000003 · form4-06292026_080608.xml · nonDerivative · entry 1

Middleton Fred A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 1,063,272

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP ("SVP VI Co-Investment, LP", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Securities"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001189022-26-000002 · form4-06292026_080605.xml · nonDerivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,604,650

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001576244-26-000004 · form4-06292026_080603.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,435

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001823197-25-000003 · form4-10142025_041014.xml · derivative · entry 1

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 937

Underlying: Common Stock · 937 shares

Expires 2035-10-12

F1 · derivative.exercise_date: Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments.

SEC source: 0001576244-25-000007 · form4-09222025_090901.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 84,150

SEC source: 0001576244-25-000005 · form4-09172025_090902.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 81,650

F1 · price: The weighted average purchase price for the transaction reported was $2.6779, and the range of prices were between $2.65 and $2.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001576244-25-000003 · form4-09152025_040948.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 78,250

SEC source: 0001415889-25-024256 · form4-09112025_120901.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 73,250

F1 · price: The weighted average purchase price for the transaction reported was $3.1488, and the range of prices were between $2.75 and $3.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-023364 · form4-09022025_050918.xml · nonDerivative · entry 2

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 70,907

SEC source: 0001415889-25-023364 · form4-09022025_050918.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 70,107

F1 · price: The weighted average purchase price for the transaction reported was $2.8630, and the range of prices were between $2.75 and $2.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022850 · form4-08252025_090801.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 60,907

F1 · price: The weighted average purchase price for the transaction reported was $2.7928, and the range of prices were between $2.75 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022550 · form4-08212025_120804.xml · derivative · entry 9

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,750

Underlying: Common Stock · 15,000 shares

Expires 2035-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 3

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,706

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 2

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 57,399

SEC source: 0001415889-25-022549 · form4-08212025_120801.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,539

F1 · price: The weighted average purchase price for the transaction reported was $2.8194, and the range of prices were between $2.74 and $2.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022550 · form4-08212025_120804.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 55,399

SEC source: 0001415889-25-022159 · form4-08182025_120801.xml · nonDerivative · entry 2

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,976

F2 · price: The weighted average purchase price for the transaction reported was $2.7930, and the range of prices were between $2.70 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022261 · form4-08192025_010801.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 54,399

F1 · shares: The weighted average purchase price for the transaction reported was $2.8977, and the range of prices were between $2.80 and $2.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022159 · form4-08182025_120801.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,584

F1 · price: The weighted average purchase price for the transaction reported was $2.585, and the range of prices were between $2.57 and $2.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-020458 · form4-07292025_040701.xml · nonDerivative · entry 2

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,944

SEC source: 0001415889-25-020458 · form4-07292025_040701.xml · nonDerivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

F1 · kind: The sale of the common stock of CalciMedica, Inc. (the "Issuer") by the spouse of the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person's spouse at a price of $1.85 per share on July 1, 2025. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $1,799.83, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.